Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) will release its third-quarter 2025 financial results after market close on Wednesday, October 22, 2025. The company will host a conference call to discuss results and corporate updates beginning at 4:30 p.m. Eastern Time the same day.

Investors may join by phone (U.S. dial-in 844-850-0543; outside U.S. 412-317-5199) or listen live via the company webcast on the Viking IR Webcasts page. A telephone replay will be available through October 29, 2025 with replay access code 8625334, and a webcast archive will be posted on the Webcasts page for 30 days.

Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time 

SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2025 after the market close on Wednesday, October 22, 2025.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, October 22, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until October 29, 2025, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #8625334. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2025-on-october-22-2025-302584128.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics (VKTX) report Q3 2025 results and hold the conference call?

Viking will release Q3 2025 results after market close and hold the call on October 22, 2025 at 4:30 p.m. ET.

How can I join the Viking (VKTX) October 22, 2025 conference call by phone?

Dial 844-850-0543 from the U.S. or 412-317-5199 from outside the U.S. to join the live call.

Where can I listen to the Viking (VKTX) webcast for the Q3 2025 results?

Listen live or access the archive via the Viking investor relations Webcasts page at ir.vikingtherapeutics.com/webcasts.

Will there be a replay of the Viking (VKTX) October 22, 2025 earnings call and how long is it available?

A telephone replay is available until October 29, 2025; the webcast archive will remain on the Webcasts page for 30 days.

What is the replay access code for Viking (VKTX) Q3 2025 conference call?

Use replay access code 8625334 when dialing the U.S. replay number 877-344-7529.

What will Viking (VKTX) cover during the October 22, 2025 conference call?

The company will discuss third-quarter 2025 financial results and provide general corporate updates.